<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5114">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01171820</url>
  </required_header>
  <id_info>
    <org_study_id>05-369 Diabetic Sub-study</org_study_id>
    <nct_id>NCT01171820</nct_id>
  </id_info>
  <brief_title>SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study)</brief_title>
  <official_title>SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Clinical Evaluation is a continuation in the assessment of the
      performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in
      the treatment of patients with de novo coronary artery lesions in patients (Diabetic
      sub-study).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SPIRIT V Clinical Evaluation consists of two concurrent studies,the Diabetic sub-study
      and the Registry.

      The SPIRIT V Diabetic sub-study is a prospective, randomized, active-controlled, single
      blind, parallel two-arm multi-center study comparing the XIENCE V® EECSS to the TAXUS®
      Liberté™ in the treatment of diabetic patients with coronary artery lesions who will fulfill
      the eligibility criteria. Approximately 300 patients will be randomized (2:1) against the
      TAXUS® Liberté™ coronary stent system. These patients will be recruited in up to 40 selected
      sites.

      The long term safety and efficacy of the XIENCE V EECSS have been demonstrated in the SPIRIT
      FIRST trial up to 5 years, the SPIRIT II trial up to 4 years, and in the SPIRIT III
      Randomized Control Trial (RCT) up to 3 years. In addition, these pre-approval studies have
      shown low rates of Target Vessel Failure and Major Adverse Cardiac Events (MACE) that were
      observed to plateau or gradually decline after about 1 year and were consistently lower than
      the comparator arm of each study. This benefit in MACE is sustained for up to 5 years and is
      also independent of the first year results.

      The post approval SPIRIT V study demonstrated that the use of the XIENCE EECSS in complex
      lesions in a real-world population resulted in 1 year MACE, Stent Thrombosis and Target
      Lesion Revascularization rates that are comparable to those of the previously mentioned
      pre-approval studies which included patients with more restricted inclusion / exclusion
      criteria.

      Therefore, based on existing data from these trials, Abbott Vascular has decided to
      discontinue further follow up in the SPIRIT V Diabetic study after 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>In-stent Late Loss(LL)</measure>
    <time_frame>270 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>In-stent minimal lumen diameter (MLD) post-procedure minus (-) in-stent MLD at follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Device Success</measure>
    <time_frame>Acute: At time of index procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Successful delivery and deployment of the study stent (in overlapping stent setting a successful delivery and deployment of the first and second study stent) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable), without use of a device outside the assigned treatment strategy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Procedure Success</measure>
    <time_frame>Acute: At time of index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Successful delivery and deployment of the study stent or stents at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable) and/or using any adjunctive device without the occurrence of cardiac death, MI attributed to the target vessel and/or CI-TLR during the hospital stay with a maximum of first seven days post index procedure. In multiple lesion setting each lesion must meet clinical procedure success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment Late Loss</measure>
    <time_frame>270 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>In-segment minimal lumen diameter (MLD) post-procedure minus (-) in segment MLD at follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proximal Late Loss</measure>
    <time_frame>270 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proximal Minimum Lumen Diameter (MLD) post-procedure minus proximal MLD at follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal Late Loss</measure>
    <time_frame>270 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Distal Minimum Lumen Diameter (MLD) post-procedure minus distal MLD at follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent Angiographic Binary Restenosis Rate</measure>
    <time_frame>270 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent of patients with a follow-up percent diameter stenosis of ≥ 50% per Quantitative Coronary Angiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment Angiographic Binary Restenosis Rate</measure>
    <time_frame>270 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent of patients with a follow-up percent diameter stenosis of ≥ 50% per Quantitative Coronary Angiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent Percent Diameter Stenosis</measure>
    <time_frame>270 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>This number represents the average of percent diameter stenosis found on examination of all the lesions analyzed.
This value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by Qualitative Coronary Angiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment Percent Diameter Stenosis</measure>
    <time_frame>270 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>This number represents the average of percent diameter stenosis found on examination of all the lesions analyzed.
This value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by Qualitative Coronary Angiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Stent Thrombosis (Confirmed/Definite, Probable, Possible)</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A thrombosis is blood clot that forms on the stent. This outcome measures the percentage of participants found to have this condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Stent Thrombosis (Confirmed/Definite, Probable, Possible)</measure>
    <time_frame>240 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A thrombosis is blood clot that forms on the stent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Stent Thrombosis (Confirmed/Definite, Probable, Possible)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A thrombosis is blood clot that forms on the stent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Revascularizations (TLR/TVR/Any Revascularization) Both Clinically-indicated and Not Clinically-indicated.</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Revascularizations (TLR/TVR/Any Revascularization) Both Clinically-indicated and Not Clinically-indicated.</measure>
    <time_frame>240 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Revascularizations (TLR/TVR/Any Revascularization) Both Clinically-indicated and Not Clinically-indicated.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Composite Rate of Cardiac Death, Myocardial Infarction (MI) Attributed to the Target Vessel and Clinical-indicated Target Lesion Revascularization (CI-TLR)</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Composite Rate of Cardiac Death, Myocardial Infarction (MI) Attributed to the Target Vessel and Clinical-indicated Target Lesion Revascularization (CI-TLR)</measure>
    <time_frame>240 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Composite Rate of Cardiac Death, Myocardial Infarction (MI) Attributed to the Target Vessel and Clinical-indicated Target Lesion Revascularization (CI-TLR)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Composite Rate of All Death, MI and Target Vessel Revascularization (TVR)</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Composite Rate of All Death, MI and Target Vessel Revascularization (TVR)</measure>
    <time_frame>240 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Composite Rate of All Death, MI and Target Vessel Revascularization (TVR)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Composite Rate of All Death, Any Myocardial Infarction (MI) and Any Revascularization (TLR/TVR/Non TVR)</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Composite Rate of All Death, Any Myocardial Infarction (MI) and Any Revascularization (TLR/TVR/Non TVR)</measure>
    <time_frame>240 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Composite Rate of All Death, Any Myocardial Infarction (MI) and Any Revascularization (TLR/TVR/Non TVR)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">324</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>TAXUS® Liberté™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>XIENCE V® EECSS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAXUS® Liberté™</intervention_name>
    <description>Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes</description>
    <arm_group_label>TAXUS® Liberté™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE V® EECSS</intervention_name>
    <description>Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes</description>
    <arm_group_label>XIENCE V® EECSS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 18 years

          -  able to verbally confirm understanding of risks, benefits and treatment alternatives
             of receiving the XIENCE V® EECSS and he/she or his/her legally authorized
             representative provides written informed consent prior to any study related
             procedure, as approved by the appropriate Medical Ethics Committee of the respective
             clinical site

          -  diagnosed with diabetes, as documented by medical history.

          -  evidence of myocardial ischemia

          -  acceptable candidate for CABG surgery

          -  agree to undergo all CIP-required follow-up examinations

          -  artery morphology and disease is suitable to be optimally treated with a maximum of 4
             planned stents

          -  maximum of one, de novo, target lesion per native major epicardial vessel or side
             branch

          -  target vessel reference diameter must be between 2.25 mm and 4.0 mm by visual
             estimate

          -  target lesion ≤ 28 mm in length by visual estimate

          -  target lesion must be in a major artery or branch with a visually estimated stenosis
             of &gt; 50% and &lt; 100% and a TIMI flow &gt; 1

        Exclusion Criteria:

          -  known diagnosis of AMI within 72 hours preceding the index procedure

          -  current unstable arrhythmias

          -  LVEF &lt; 30%

          -  received a heart or any other organ transplant or is on a waiting list for any organ
             transplant

          -  receiving or scheduled to receive chemotherapy or radiation therapy within 30 days
             prior to or after the procedure.

          -  receiving immunosuppression therapy or has known immunosuppressive or autoimmune
             disease

          -  known hypersensitivity or contraindication to specific agents

          -  elective surgery is planned within the first 9 months after the procedure that will
             require discontinuing either aspirin or clopidogrel

          -  platelet count limits, WBC limits or documented or suspected liver disease

          -  renal insufficiency

          -  history of bleeding diathesis or coagulopathy or will refuse blood transfusions

          -  CVA or TIA within the past 6 months

          -  significant GI or urinary bleed within the past 6 months

          -  history of other medical illness (e.g., cancer or congestive heart failure) or known
             history of substance abuse that may cause non-compliance with the CIP, confound the
             data interpretation or is associated with a limited life expectancy (i.e. less than
             one year)

        Target lesion meets any of the following criteria:

          -  In-stent restenotic

          -  aorto-ostial location (within 3 mm)

          -  left main location

          -  located within 2 mm of the origin of the LAD or LCX

          -  located within an arterial or saphenous vein graft or distal to a diseased arterial
             or saphenous vein graft (defined as vessel irregularity per angiogram and &gt; 20%
             stenosed lesion by visual estimation)

          -  lesion involving a side branch ≥ 2.5 mm in diameter

          -  lesion involving a side branch with &gt; 50% stenosis by visual estimation Lesion
             involving a side branch requiring predilatation

          -  located in a major epicardial vessel that has been previously treated with
             brachytherapy

          -  located in a major epicardial vessel or a side branch that has been previously
             treated with any type of percutaneous intervention (e.g., balloon angioplasty,
             cutting balloon, atherectomy), &lt; 9 months prior to the index procedure

          -  total occlusion (TIMI flow 0), prior to wire crossing

          -  excessive tortuosity proximal to or within the lesion

          -  extreme angulation (≥ 90%) proximal to or within the lesion

          -  heavy calcification

        The target vessel contains visible thrombus

        Patient has a high probability that a procedure other than pre-dilatation, stenting and
        post-dilatation will be required at the time of index procedure for treatment of the
        target vessel (e.g. brachytherapy)

        Patient has additional clinically significant lesion(s) (&gt; 50% diameter stenosis) in a
        target vessel or side branch for which an intervention within 9 months after the index
        procedure may be required
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eberhard Grube, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Heart Center Rhein-Ruhr, Essen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Upendra Kaul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fortis Hospital, New Delhi, India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Salzburger Landeskliniken</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. - Hopital Michallon</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lille - Hôpital Cardiologique</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum</name>
      <address>
        <city>Bernau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lukas Krankenhaus Neuss</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Siegburg GmbH</name>
      <address>
        <city>Siegburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Riuniti</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile</name>
      <address>
        <city>Mirano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Gdi Dio Salerno</name>
      <address>
        <city>Salerno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Jantung Negara</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstad Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Bydgoszcz</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General De Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Belvigte de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wessex Cardiac Unit</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/NCT00402272?term=SPIRIT+V&amp;rank=1</url>
    <description>SPIRIT V registry arm</description>
  </link>
  <verification_date>October 2010</verification_date>
  <lastchanged_date>October 1, 2010</lastchanged_date>
  <firstreceived_date>April 1, 2010</firstreceived_date>
  <firstreceived_results_date>August 31, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Ellen Travis</name_title>
    <organization>Abbott Vascular</organization>
  </responsible_party>
  <keyword>drug eluting stents</keyword>
  <keyword>stents</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>total coronary occlusion</keyword>
  <keyword>coronary artery restenosis</keyword>
  <keyword>stent thrombosis</keyword>
  <keyword>vascular disease</keyword>
  <keyword>myocardial ischemia</keyword>
  <keyword>coronary artery stenosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>324 subjects were recruited at 32 sites. Eligible subjects invited to participate, in-hospital or in-clinic and required to provide signed informed consent prior to enrollment. Final eligibility based on angiographic inclusion criteria prior to the intended procedure. Dates of recruitment: April 28, 2007 to October 6, 2008.</recruitment_details>
      <pre_assignment_details>Subjects were randomized via telephone randomization and stratified by insulin treatment status, number of lesions treated-single vs. multiple. Randomization only occurred after verification of the inclusion/exclusion criteria and successful pre-dilatation. See the Eligibility Criteria (inclusion/exclusion criteria) for details.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TAXUS® Liberté™</title>
          <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
        </group>
        <group group_id="P2">
          <title>XIENCE V® EECSS</title>
          <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="218"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="212"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>1-Year Missed Visit without Official Ter</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TAXUS® Liberté™</title>
          <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
        </group>
        <group group_id="B2">
          <title>XIENCE V® EECSS</title>
          <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="106"/>
                <measurement group_id="B2" value="218"/>
                <measurement group_id="B3" value="324"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="49"/>
                <measurement group_id="B2" value="102"/>
                <measurement group_id="B3" value="151"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="57"/>
                <measurement group_id="B2" value="116"/>
                <measurement group_id="B3" value="173"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="65.75" spread="8.95"/>
                <measurement group_id="B2" value="65.32" spread="9.61"/>
                <measurement group_id="B3" value="65.46" spread="9.39"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
                <measurement group_id="B2" value="66"/>
                <measurement group_id="B3" value="101"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="71"/>
                <measurement group_id="B2" value="152"/>
                <measurement group_id="B3" value="223"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>France</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Thailand</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Spain</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="57"/>
                <measurement group_id="B2" value="87"/>
                <measurement group_id="B3" value="144"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Poland</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="25"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Malaysia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Austria</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Israel</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Netherlands</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Germany</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="36"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>United Kingdom</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Italy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="43"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>In-stent Late Loss(LL)</title>
        <description>In-stent minimal lumen diameter (MLD) post-procedure minus (-) in-stent MLD at follow-up</description>
        <time_frame>270 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patients were required to have angiographic follow-up to provide this endpoint information. Some patients not completing the study, did not have this follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="218"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of lesions analyzed</title>
            <units>lesions</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="110"/>
                  <measurement group_id="O2" value="249"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>In-stent Late Loss(LL)</title>
            <description>In-stent minimal lumen diameter (MLD) post-procedure minus (-) in-stent MLD at follow-up</description>
            <units>millimeters</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.39" spread="0.49"/>
                  <measurement group_id="O2" value="0.19" spread="0.37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Device Success</title>
        <description>Successful delivery and deployment of the study stent (in overlapping stent setting a successful delivery and deployment of the first and second study stent) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable), without use of a device outside the assigned treatment strategy.</description>
        <time_frame>Acute: At time of index procedure</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="218"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Device Success</title>
            <description>Successful delivery and deployment of the study stent (in overlapping stent setting a successful delivery and deployment of the first and second study stent) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable), without use of a device outside the assigned treatment strategy.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="98.50" lower_limit="94.67" upper_limit="99.82"/>
                  <measurement group_id="O2" value="97.58" lower_limit="95.07" upper_limit="99.02"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Procedure Success</title>
        <description>Successful delivery and deployment of the study stent or stents at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable) and/or using any adjunctive device without the occurrence of cardiac death, MI attributed to the target vessel and/or CI-TLR during the hospital stay with a maximum of first seven days post index procedure. In multiple lesion setting each lesion must meet clinical procedure success.</description>
        <time_frame>Acute: At time of index procedure</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="218"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Procedure Success</title>
            <description>Successful delivery and deployment of the study stent or stents at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable) and/or using any adjunctive device without the occurrence of cardiac death, MI attributed to the target vessel and/or CI-TLR during the hospital stay with a maximum of first seven days post index procedure. In multiple lesion setting each lesion must meet clinical procedure success.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="93.14" lower_limit="86.37" upper_limit="97.20"/>
                  <measurement group_id="O2" value="96.70" lower_limit="93.32" upper_limit="98.66"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-segment Late Loss</title>
        <description>In-segment minimal lumen diameter (MLD) post-procedure minus (-) in segment MLD at follow-up</description>
        <time_frame>270 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patients were required to have angiographic follow-up to provide this endpoint information. Some patients not completing the study, did not have this follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="281"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of lesions analyzed</title>
            <units>lesions</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="109"/>
                  <measurement group_id="O2" value="249"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>In-segment Late Loss</title>
            <description>In-segment minimal lumen diameter (MLD) post-procedure minus (-) in segment MLD at follow-up</description>
            <units>millimeters</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.22" spread="0.45"/>
                  <measurement group_id="O2" value="0.12" spread="0.42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proximal Late Loss</title>
        <description>Proximal Minimum Lumen Diameter (MLD) post-procedure minus proximal MLD at follow-up</description>
        <time_frame>270 day</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patients were required to have angiographic follow-up to provide this endpoint information. Some patients not completing the study, did not have this follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="218"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of lesions analyzed</title>
            <units>lesions</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="104"/>
                  <measurement group_id="O2" value="241"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proximal Late Loss</title>
            <description>Proximal Minimum Lumen Diameter (MLD) post-procedure minus proximal MLD at follow-up</description>
            <units>millimeters</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.17" spread="0.33"/>
                  <measurement group_id="O2" value="0.13" spread="0.39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distal Late Loss</title>
        <description>Distal Minimum Lumen Diameter (MLD) post-procedure minus distal MLD at follow-up</description>
        <time_frame>270 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patients were required to have angiographic follow-up to provide this endpoint information. Some patients not completing the study, did not have this follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="218"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of lesions analyzed</title>
            <units>lesions</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="107"/>
                  <measurement group_id="O2" value="247"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Distal Late Loss</title>
            <description>Distal Minimum Lumen Diameter (MLD) post-procedure minus distal MLD at follow-up</description>
            <units>millimeters</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.0" spread="0.34"/>
                  <measurement group_id="O2" value="0.0" spread="0.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-stent Angiographic Binary Restenosis Rate</title>
        <description>Percent of patients with a follow-up percent diameter stenosis of ≥ 50% per Quantitative Coronary Angiogram.</description>
        <time_frame>270 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patients were required to have angiographic follow-up to provide this endpoint information. Some patients not completing the study, did not have this follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="218"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of lesions analyzed</title>
            <units>lesions</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="115"/>
                  <measurement group_id="O2" value="261"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>In-stent Angiographic Binary Restenosis Rate</title>
            <description>Percent of patients with a follow-up percent diameter stenosis of ≥ 50% per Quantitative Coronary Angiogram.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6.1" lower_limit="2.48" upper_limit="12.14"/>
                  <measurement group_id="O2" value="3.1" lower_limit="1.33" upper_limit="5.95"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-segment Angiographic Binary Restenosis Rate</title>
        <description>Percent of patients with a follow-up percent diameter stenosis of ≥ 50% per Quantitative Coronary Angiogram.</description>
        <time_frame>270 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patients were required to have angiographic follow-up to provide this endpoint information. Some patients not completing the study, did not have this follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="218"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of lesions analyzed</title>
            <units>lesions</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="110"/>
                  <measurement group_id="O2" value="255"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>In-segment Angiographic Binary Restenosis Rate</title>
            <description>Percent of patients with a follow-up percent diameter stenosis of ≥ 50% per Quantitative Coronary Angiogram.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6.4" lower_limit="2.60" upper_limit="12.67"/>
                  <measurement group_id="O2" value="7.5" lower_limit="4.55" upper_limit="11.39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-stent Percent Diameter Stenosis</title>
        <description>This number represents the average of percent diameter stenosis found on examination of all the lesions analyzed.
This value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by Qualitative Coronary Angiogram.</description>
        <time_frame>270 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patients were required to have angiographic follow-up to provide this endpoint information. Some patients not completing the study, did not have this follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="218"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of lesions analyzed</title>
            <units>lesions</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="115"/>
                  <measurement group_id="O2" value="261"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>In-stent Percent Diameter Stenosis</title>
            <description>This number represents the average of percent diameter stenosis found on examination of all the lesions analyzed.
This value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by Qualitative Coronary Angiogram.</description>
            <units>Percent diameter stenosis</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20.70" spread="16.02"/>
                  <measurement group_id="O2" value="14.33" spread="13.34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-segment Percent Diameter Stenosis</title>
        <description>This number represents the average of percent diameter stenosis found on examination of all the lesions analyzed.
This value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by Qualitative Coronary Angiogram.</description>
        <time_frame>270 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patients were required to have angiographic follow-up to provide this endpoint information. Some patients not completing the study, did not have this follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="218"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of lesions analyzed</title>
            <units>lesions</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="115"/>
                  <measurement group_id="O2" value="261"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>In-segment Percent Diameter Stenosis</title>
            <description>This number represents the average of percent diameter stenosis found on examination of all the lesions analyzed.
This value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by Qualitative Coronary Angiogram.</description>
            <units>Percent diameter stenosis</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23.87" spread="15.25"/>
                  <measurement group_id="O2" value="22.42" spread="15.05"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Stent Thrombosis (Confirmed/Definite, Probable, Possible)</title>
        <description>A thrombosis is blood clot that forms on the stent. This outcome measures the percentage of participants found to have this condition.</description>
        <time_frame>30 days</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="218"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adjudicated Stent Thrombosis (Confirmed/Definite, Probable, Possible)</title>
            <description>A thrombosis is blood clot that forms on the stent. This outcome measures the percentage of participants found to have this condition.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.94" lower_limit="0.02" upper_limit="5.14"/>
                  <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="1.68"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Stent Thrombosis (Confirmed/Definite, Probable, Possible)</title>
        <description>A thrombosis is blood clot that forms on the stent</description>
        <time_frame>240 days</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="217"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adjudicated Stent Thrombosis (Confirmed/Definite, Probable, Possible)</title>
            <description>A thrombosis is blood clot that forms on the stent</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.83" lower_limit="0.59" upper_limit="8.05"/>
                  <measurement group_id="O2" value="0.46" lower_limit="0.01" upper_limit="2.54"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Stent Thrombosis (Confirmed/Definite, Probable, Possible)</title>
        <description>A thrombosis is blood clot that forms on the stent</description>
        <time_frame>1 year</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="104"/>
                  <measurement group_id="O2" value="215"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adjudicated Stent Thrombosis (Confirmed/Definite, Probable, Possible)</title>
            <description>A thrombosis is blood clot that forms on the stent</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.88" lower_limit="0.60" upper_limit="8.20"/>
                  <measurement group_id="O2" value="0.47" lower_limit="0.01" upper_limit="2.56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Revascularizations (TLR/TVR/Any Revascularization) Both Clinically-indicated and Not Clinically-indicated.</title>
        <time_frame>30 days</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="218"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adjudicated Revascularizations (TLR/TVR/Any Revascularization) Both Clinically-indicated and Not Clinically-indicated.</title>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.83" lower_limit="0.59" upper_limit="8.05"/>
                  <measurement group_id="O2" value="1.38" lower_limit="0.28" upper_limit="3.97"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Revascularizations (TLR/TVR/Any Revascularization) Both Clinically-indicated and Not Clinically-indicated.</title>
        <time_frame>240 days</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="217"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adjudicated Revascularizations (TLR/TVR/Any Revascularization) Both Clinically-indicated and Not Clinically-indicated.</title>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.72" lower_limit="1.55" upper_limit="10.67"/>
                  <measurement group_id="O2" value="6.45" lower_limit="3.57" upper_limit="10.59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Revascularizations (TLR/TVR/Any Revascularization) Both Clinically-indicated and Not Clinically-indicated.</title>
        <time_frame>1 year</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="104"/>
                  <measurement group_id="O2" value="215"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adjudicated Revascularizations (TLR/TVR/Any Revascularization) Both Clinically-indicated and Not Clinically-indicated.</title>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14.42" lower_limit="15.70" upper_limit="26.99"/>
                  <measurement group_id="O2" value="20.93" lower_limit="8.30" upper_limit="22.67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Composite Rate of Cardiac Death, Myocardial Infarction (MI) Attributed to the Target Vessel and Clinical-indicated Target Lesion Revascularization (CI-TLR)</title>
        <time_frame>30 days</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="218"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adjudicated Composite Rate of Cardiac Death, Myocardial Infarction (MI) Attributed to the Target Vessel and Clinical-indicated Target Lesion Revascularization (CI-TLR)</title>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7.55" lower_limit="3.31" upper_limit="14.33"/>
                  <measurement group_id="O2" value="2.29" lower_limit="0.75" upper_limit="5.27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Composite Rate of Cardiac Death, Myocardial Infarction (MI) Attributed to the Target Vessel and Clinical-indicated Target Lesion Revascularization (CI-TLR)</title>
        <time_frame>240 days</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="217"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adjudicated Composite Rate of Cardiac Death, Myocardial Infarction (MI) Attributed to the Target Vessel and Clinical-indicated Target Lesion Revascularization (CI-TLR)</title>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9.43" lower_limit="4.62" upper_limit="16.67"/>
                  <measurement group_id="O2" value="5.53" lower_limit="2.89" upper_limit="9.46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Composite Rate of Cardiac Death, Myocardial Infarction (MI) Attributed to the Target Vessel and Clinical-indicated Target Lesion Revascularization (CI-TLR)</title>
        <time_frame>1 year</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="104"/>
                  <measurement group_id="O2" value="215"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adjudicated Composite Rate of Cardiac Death, Myocardial Infarction (MI) Attributed to the Target Vessel and Clinical-indicated Target Lesion Revascularization (CI-TLR)</title>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12.50" lower_limit="6.83" upper_limit="20.43"/>
                  <measurement group_id="O2" value="11.16" lower_limit="7.28" upper_limit="16.15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Composite Rate of All Death, MI and Target Vessel Revascularization (TVR)</title>
        <time_frame>30 days</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="218"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adjudicated Composite Rate of All Death, MI and Target Vessel Revascularization (TVR)</title>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8.49" lower_limit="3.96" upper_limit="15.51"/>
                  <measurement group_id="O2" value="2.29" lower_limit="0.75" upper_limit="5.27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Composite Rate of All Death, MI and Target Vessel Revascularization (TVR)</title>
        <time_frame>240 days</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="217"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adjudicated Composite Rate of All Death, MI and Target Vessel Revascularization (TVR)</title>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11.32" lower_limit="5.99" upper_limit="18.94"/>
                  <measurement group_id="O2" value="6.45" lower_limit="3.57" upper_limit="10.59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Composite Rate of All Death, MI and Target Vessel Revascularization (TVR)</title>
        <time_frame>1 year</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="110"/>
                  <measurement group_id="O2" value="249"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adjudicated Composite Rate of All Death, MI and Target Vessel Revascularization (TVR)</title>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16.35" lower_limit="9.82" upper_limit="24.88"/>
                  <measurement group_id="O2" value="16.28" lower_limit="11.61" upper_limit="21.91"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Composite Rate of All Death, Any Myocardial Infarction (MI) and Any Revascularization (TLR/TVR/Non TVR)</title>
        <time_frame>30 days</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="218"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adjudicated Composite Rate of All Death, Any Myocardial Infarction (MI) and Any Revascularization (TLR/TVR/Non TVR)</title>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10.38" lower_limit="5.30" upper_limit="17.81"/>
                  <measurement group_id="O2" value="3.21" lower_limit="1.30" upper_limit="6.50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Composite Rate of All Death, Any Myocardial Infarction (MI) and Any Revascularization (TLR/TVR/Non TVR)</title>
        <time_frame>240 days</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="217"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adjudicated Composite Rate of All Death, Any Myocardial Infarction (MI) and Any Revascularization (TLR/TVR/Non TVR)</title>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14.15" lower_limit="8.14" upper_limit="22.26"/>
                  <measurement group_id="O2" value="9.68" lower_limit="6.09" upper_limit="14.41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Composite Rate of All Death, Any Myocardial Infarction (MI) and Any Revascularization (TLR/TVR/Non TVR)</title>
        <time_frame>1 year</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAXUS® Liberté™</title>
            <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V® EECSS</title>
            <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="104"/>
                  <measurement group_id="O2" value="215"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adjudicated Composite Rate of All Death, Any Myocardial Infarction (MI) and Any Revascularization (TLR/TVR/Non TVR)</title>
            <units>Percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23.08" lower_limit="15.38" upper_limit="32.36"/>
                  <measurement group_id="O2" value="24.19" lower_limit="18.62" upper_limit="30.48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>There were 324 (218 XV, 106 TX) total patients in the dataset. To qualify as an At-Risk patient, the patient must have completed the study AND/OR have at least one adverse event. Applying this rule, the At-Risk population therefore totaled 215 XV and 105 TX and is not equal to the number of patients enrolled.</desc>
      <group_list>
        <group group_id="E1">
          <title>TAXUS® Liberté™</title>
          <description>Patients recieving the TAXUS® Liberté™ stent during PCI</description>
        </group>
        <group group_id="E2">
          <title>XIENCE V® EECSS</title>
          <description>Patients recieving the XIENCE V® EECSS stent during PCI</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Angina pectoris</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="105"/>
                <counts group_id="E2" events="29" subjects_affected="25" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>In-stent coronary artery restenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Myocardial infarction, acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Noncardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Instent coronary artery restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac stress test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Troponin T</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Hodgkins disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Lip andor oral cavity cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Peritoneal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Vocal cord disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Coronary revascularisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus management</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="105"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ellen Travis</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>408-845-1512</phone>
      <email>Ellen.Travis@av.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
